I last reviewed Home Depot (HD) in this August 21, 2025 post following the release of Q2 2025 financial results. In that post, I include metrics for prior periods so we can compare HD's performance over time. I include these previously provided results thus eliminating the need to navigate between posts. When I composed my [...]
The return on my Paycom (PAYC) investment has been less than stellar. The company's underlying fundamentals and growth potential, however, remain sound. Given this, I acquired an additional 100 shares @ $162.1148/share on November 6, 2025 in a 'Core' account in the FFJ Portfolio. I last reviewed this existing holding in my May 8, 2025 [...]
When I last reviewed Merck & Co. (MRK) in this August 4, 2023 post, the most current results were for Q2 and YTD2023. We now have MRK's Q2 and YTD2025 results released on October 30, 2025 thus prompting me to revisit this existing holding. On October 28 I increased my exposure with the purchase of [...]
When I last reviewed Paychex (PAYX) in this March 27, 2025 post, the most current financial information was for Q3 and YTD2025. The March 26, 2025 closing share price was ~$150.20 and I thought a fair value was in the low-mid ~$130s. Fast forward to November 5, 2025. We now have PAYX's Q1 2026 results [...]
On October 30, 2025, I disclose in my Exposure Increased As ADP Valuation Improves my decision to acquire an additional 200 shares @ $269.78 in a 'Core' account in the FFJ Portfolio on October 29. I conclude that post stating: I plan to acquire additional shares if ADP's valuation remains attractive. As luck would have [...]
I recently covered Cintas (CTAS) in this my September 24, 2025 post. The reason for revisiting CTAS so soon is to disclose that on November 3, 2025 I acquired an additional 100 shares @ ~$181.455 in a 'Side' account in the FFJ Portfolio. My total exposure is now 700 shares. On October 28, CTAS released [...]
I last reviewed Rollins (ROL) in this June 27, 2025 post in which I state: Rollins (ROL) may not appeal to some investors because the nature of its business is not 'sexy'. Sometimes, however, 'ho hum' businesses can offer investors the potential for very reasonable long-term total shareholder returns. Through its family of brands, ROL [...]
When I last reviewed Intercontinental Exchange (ICE) in this August 3, 2024 post, I concluded that shares were no longer undervalued. At the time of that post, ICE had just released its Q2 and YTD2024 results on August 1, 2024. I now revisit this existing holding given the release of Q3 and YTD2025 results on [...]
I last reviewed Thermo Fisher (TMO) in this July 24, 2025 post. In that post I express disappointment in the share price surge. The share price had risen to ~$475 at the July 24 market close yet as recently as July 7, 2025, I purchased 75 shares @ $421.9667 share in a 'Core' account in [...]
In my March 27, 2024 Automatic Data Processing (ADP) guest post at Dividend Power I conclude shares are overvalued. I have been an ADP shareholder for decades. The majority of my exposure is through a tax efficient Registered Retirement Savings Plan (RRSP) account for which I do not disclose details. I have made no additional [...]
